ClinicalTrials.gg
CompletedNCT04696393Updated Apr 13, 2021

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

A Phase 1 interventional study of Mitapivat tablet in Healthy Volunteers, sponsored by Agios Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-13.

Sponsored by Agios Pharmaceuticals, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2021, 5 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

The primary purpose of this study is to characterize and compare the pharmacokinetic profiles of mitapivat following a single dose administration of 100 mg mitapivat in two tablet formulations (50 mg and 100 mg tablet strengths) in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has the ability to understand the requirements of the study and a willingness to comply with all study procedures and has provided written before any study-related procedures are conducted, and is willing to comply with all study procedures for the duration of the study;
  • Has a (BMI) ≥18 and ≤32 kilograms per square meter (kg/m\^2), at screening;
  • Has a body weight ≥50 kg at screening;
  • Is medically healthy, with no conditions or abnormalities, as determined by the investigator or designee, through evaluation of medical history and vital sign measurements, 12-lead results, physical examination findings, and clinical laboratory test results (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in;
  • If female:

    • Is of and agrees to either abstain from sexual intercourse with a male partner or agrees to use a highly effective form of , beginning at screening and continuing throughout the study and for 28 days after dosing or is (defined as 12 months or more continuously with no menses), or
    • Has a documented medical history of tubal ligation or hysterectomy;
    • The following are considered highly effective forms of contraception: hormonal oral contraceptives, injectables, and patches; intrauterine devices; double barrier methods (synthetic condom, diaphragm, or cervical cap used with spermicidal foam, cream, or gel); and male partner sterilization;
  • If male (even if vasectomized):

    • Agrees to either abstain from sexual intercourse with a female partner, or
    • Agrees to use a highly effective form of contraception (as defined above), starting at screening and continuing until 90 days after the final dose of mitapivat, and
    • Agrees to not donate sperm throughout the entirety of the study until 90 days after the final dose of mitapivat;
  • Agrees to abstain from any alcohol consumption, starting 72 hours prior to check-in and continuing until the follow-up telephone call;
  • Agrees to refrain from marijuana- or cannabinol-containing products for 7 days prior to screening until after the follow-up telephone call.

Exclusion criteria

Exclusion Criteria:

  • At screening, presents with a condition or has a medical history that, in the opinion of the investigator, may potentially interfere with study drug absorption, distribution, metabolism, and/or excretion (eg, malabsorption [including due to cystic fibrosis, lactose intolerance, celiac disease]);
  • At screening, presents with a surgical history that, in the opinion of the investigator, may potentially interfere with study drug absorption, distribution, metabolism, and/or excretion (eg, cholecystectomy). Participants who have undergone abdominal surgery or any other major surgical procedure within 6 months prior to screening, must not be enrolled;
  • Has a history or a presence of a primary , with the exception of a malignancy that has been curatively treated and for which the participant has displayed no evidence of disease within 12 months prior to screening;
  • Has a known history or presence of liver disease;
  • Is pregnant or breastfeeding;
  • Has a positive test result for surface antigen (HBsAg), virus antibody (HCVAb), or (HIV) types 1 or 2 antibodies at screening;
  • Has liver test results including (ALT), aspartate aminotransferase (AST), alkaline phosphatase, and total that are above the at screening or check-in (out-of-range test results may be repeated once at screening and check-in, if needed);
  • Has estimated (eGFR) \<60 milliliters per minute (mL/min)/1.73 m\^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 equation;
  • Has , , or hematocrit test results that are below the lower limit of normal at screening or check-in (out-of-range test results may be repeated once at screening and check-in, if needed);
  • Has confirmed (ie, 2 consecutive measurements) systolic blood pressure (BP) >150 or \<90 millimeters of mercury (mmHg), diastolic blood pressure (BP) >90 or \<50 mmHg, and pulse rate >100 or \<45 beats per minute (bpm) at screening and check-in;
  • Has cardiac history or presence of findings as determined by the investigator at screening and check-in, including any of the following:

    • Abnormal sinus rhythm (heart rate [HR] lower than 45 bpm and higher than 100 bpm);
    • Risk factors for torsades de pointes (eg, heart failure, cardiomyopathy, or family history of long syndrome);
    • Sick sinus syndrome, second- or third-degree atrioventricular block myocardial infarction, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, or conduction abnormalities;
    • QT interval corrected for HR using Fridericia's formula (QTcF) >450 milliseconds (msec) (male participants) or >450 msec (female participants). In the event a QTcF value is outside of the reference range, it will be confirmed by 2 further repeat measurements, which will then be used to calculate a mean from the original value and the 2 repeat measurements;
    • QRS interval >110 msec, confirmed by manual over read;
    • PR interval \<120 and >220 msec;
    • Repeated or frequent syncope or vasovagal episodes;
    • Hypertension, angina, bradycardia (if assessed as clinically significant by the investigator), or severe peripheral arterial circulatory disorders;
  • Has clinically significant laboratory assessment findings, including hypokalemia, hypercalcemia, or hypomagnesemia;
  • Has an active infection requiring systemic antimicrobial therapy at any time during the screening period;
  • Has a positive urine drug screen (including cotinine) at screening or check-in;
  • Has a positive alcohol breath test result or positive urine drug screen at screening or check-in;
  • Uses or intends to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including any over-the-counter medications or herbal or nutritional supplements with the exception of vitamins, within 14 days (or 5 half-lives, whichever is longer) prior to check-in and until the follow-up telephone call, unless deemed acceptable by the investigator (or designee). Note: After first dosing, acetaminophen (up to 2 grams per 24 hours) may be administered at the discretion of the investigator or designee;
  • Has used any prescription (excluding hormone replacement therapy and hormonal ) medications, including systemic antimicrobial therapies, within 30 days (or 5 half-lives, whichever is longer) before the first dose of study drug or during the study (ie, through the follow-up telephone call);
  • Is currently enrolled in or has participated in another clinical study to receive any or marketed product or placebo within 2 months (or 5 half-lives, whichever is longer) prior to check-in;
  • Has donated blood or blood products or experienced blood loss of >450 mL within 30 days prior to check-in;
  • Has received blood products within 2 months prior to check-in;
  • Has consumed caffeine- or xanthine-containing products within 24 hours prior to first dose of study drug until after the follow-up telephone call;
  • Has consumed foods or beverages containing grapefruit or Seville oranges for 7 days prior to the first dosing and is not willing to refrain from consumption of these foods or beverages throughout the study;
  • Has ingested poppy seeds within 7 days prior to check-in until after the follow-up telephone call;
  • Has consumed vegetables from the mustard green family (eg, kale, broccoli, watercress, collard greens, kohlrabi, Brussel sprouts, and mustard greens), or charbroiled meats within 7 days prior to first dose of study drug or throughout the study;
  • Has used nicotine-containing products (eg, snuff, nicotine patch, nicotine chewing gum, mock cigarettes, vaporizers, or inhalers) within 6 months prior to screening, based on participant self-reporting, and does not agree to abstain from use until the follow-up telephone call;
  • Has a history of active alcoholism or drug/chemical abuse within 2 years prior to check-in;
  • Average alcohol consumption of >21 units per week for males and >14 units for females (1 unit is equal to approximately 1/2 pint [200 mL] of beer, or 1 small glass [100 mL] of wine, or 1 measure [25 mL] of 40% spirits);
  • Has a history of relevant drug and/or food allergies (ie, allergy to study drug or [microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, magnesium stearate, and mannitol]);
  • Has veins that are unsuitable for multiple venipunctures/cannulation, as assessed by the investigator or designee at screening;
  • Is involved in strenuous activity or contact sports within 24 hours prior to check-in or throughout the study;
  • Has any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data;
  • Has a positive test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Note: Testing will be performed according to site procedures.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Treatment Sequence 1: AB

    Participants will receive Treatment A (mitapivat 100 milligram \[mg\] tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.

    Drug: Mitapivat tablet

  • Experimental
    Treatment Sequence 1: BA

    Participants will receive Treatment B (mitapivat 2 x 50 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 1), followed by Treatment A (mitapivat 100 mg tablet formulation, orally, under fasted conditions once on Day 1 of Period 2). Each treatment period will be separated by a washout period of at least 7 days.

    Drug: Mitapivat tablet

Interventions

  • Oral tablets

    Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) of Mitapivat From Time 0 to the Last Quantifiable Concentration (AUC0-t)

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  2. AUC of Mitapivat From Time 0 Extrapolated to Infinity (AUC0-inf)

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  3. Maximum Observed Plasma Concentration (Cmax) of Mitapivat

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  4. Time to Maximum Observed Plasma Concentration (Tmax) of Mitapivat

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  5. Apparent Terminal Elimination Rate Constant (λZ) of Mitapivat

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  6. Terminal Phase Half-life (t1/2) of Mitapivat

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  7. Apparent Oral Clearance (CL/F) of Mitapivat

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

  8. Apparent Volume of Distribution (Vd/F) of Mitapivat

    Time frame: Pre-dose and multiple time points post-dose (up to 120 hours)

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Time frame: Up to approximately 18 days

  2. Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values

    Time frame: Up to approximately 18 days

  3. Number of Participants With Clinically Significant Abnormal Findings for Vital Sign Parameters

    Time frame: Up to approximately 18 days

  4. Number of Participants With Clinically Significant Abnormal Findings for 12-lead Electrocardiogram (ECG) Parameters

    Time frame: Up to approximately 18 days

  5. Number of Participants With Clinically Significant Abnormal Physical Examination Findings

    Time frame: Up to approximately 18 days

07

Study locations

1 site
  • PPD Development, LP
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Mar 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2021
First posted
Jan 6, 2021
StartActual
Jan 6, 2021
Primary completionActual
Mar 19, 2021
CompletionActual
Mar 19, 2021
Last update
Apr 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04696393
Responsible party
Sponsor
First posted
Jan 6, 2021
Start date
Jan 6, 2021
Primary completion
Mar 19, 2021
Completion
Mar 19, 2021
Last update
Apr 13, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mitapivat

Start the discussion